Company intelligence / Profile preview

Vitality Biopharma, Inc.

Cleveland, Ohio, United Statesvitality-research.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company developed a novel class of glycosylated cannabinoid prodrugs ("cannabosides") that enable site-specific delivery to the GI tract, aiming to treat conditions like inflammatory bowel disease without systemic psychoactive effects. Lead candidate VBX‑100 received FDA Orphan Drug Designation for pediatric ulcerative colitis but had not reported clinical efficacy data as of the latest public disclosures.

Therapeutic areas: GastroenterologyImmunologyNeurology
Modalities: Small molecules (specifically cannabinoid prodrugs and glycosylated cannabinoids called "cannabosides")
Industry: Biotech

Beyond the preview

Go deeper on Vitality Biopharma, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vitality Biopharma, Inc..

Explore the full profile